Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Dermata Therapeutics, Inc.

Ticker
DRMA
Sector
Industry
Report date
November 11, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Dermata's progress in clinical trials, product launches, and financing activities supporting its strategic shift to DTC and OTC skincare products.

Recent developments:
  • Dermata announced enrollment of the first participant in the Tome Clearing Treatment clinical trial in November 2026 [N1].
  • The company reported Q2 2026 financial results ahead of its first product launch in August 2026 [N3].
  • Dermata announced a private placement valued at up to $12.4 million in December 2025 [N4].
  • The first OTC acne kit launch was announced for mid-2026 [N5].
  • Dermata completed enrollment in the DMT310 Phase 3 STAR-1 trial in December 2024 [N7].
Overview

Dermata Therapeutics, Inc. focuses on developing and commercializing skincare products addressing common and underserved skin conditions. Initially centered on prescription acne treatments, the company achieved significant Phase 3 clinical trial results for its lead asset XYNGARI (DMT310). In 2025, Dermata shifted strategy to develop direct-to-consumer and B2B cosmetic and OTC skincare products, leveraging its proprietary Bioneedle technology derived from the freshwater sponge Spongilla lacustris. The company plans to launch its first cosmetic product, Tome Foundational Treatment, and an OTC acne product, Tome Clearing Treatment, in mid-2026. Sales channels include online subscriptions and medical professional offices. Dermata aims to expand its product portfolio to treat various skin diseases and build a certified professional network to support marketing and distribution. The skincare market trends favor natural, science-backed products with multifunctional benefits, aligning with Dermata's strategy.

Executive summary

Dermata Therapeutics, Inc. is a skincare company transitioning from prescription acne treatments to direct-to-consumer and B2B cosmetic and OTC products leveraging its proprietary Bioneedle technology derived from Spongilla lacustris. The company plans to launch its first cosmetic and OTC acne products under the Tome brand in mid-2026. Financially, as of September 30, 2026, Dermata reported $4.82 million in cash and equivalents, a current ratio of 4.24, and a net loss of $2.82 million with EPS of -$0.55. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for DRMA

Bull case model:

Dermata's strategic pivot from prescription acne treatments to direct-to-consumer and B2B cosmetic and OTC skincare products aligns with evolving consumer preferences for natural, effective, and accessible skincare solutions. The proprietary Bioneedle technology offers a unique ingredient platform with potential applications across multiple skin conditions and aesthetic treatments, including non-invasive delivery of botulinum toxins. Successful launches of the Tome Foundational and Clearing Treatments could establish brand presence and generate revenue through diversified sales channels. Expansion of the product portfolio and professional certification network may enhance market penetration and create recurring revenue streams. The company's strong intellectual property and exclusive supply agreements provide barriers to entry for competitors.

Bear case model:

Dermata faces risks related to the successful commercialization of its new product lines, including consumer acceptance of the Tome brand and efficacy of Bioneedle-based treatments. Regulatory challenges, despite the shift away from prescription products, may still arise for OTC and cosmetic claims. The company operates with net losses and limited cash reserves, which may constrain its ability to fund product launches and expansion without additional financing. Competition in the skincare market is intense, with many established players offering natural and science-backed products. Delays or failures in clinical trials, product development, or market adoption could adversely impact Dermata's business prospects.

Moat:

Dermata's moat is anchored in its proprietary Bioneedle technology derived from Spongilla lacustris, a unique freshwater sponge ingredient with organic and mechanical properties optimized through exclusive harvesting and processing protocols. This technology enables differentiated product offerings in cosmetic and OTC skincare, including potential non-invasive intradermal delivery of botulinum toxins. The company's intellectual property portfolio, exclusive raw material supply agreements, and planned certification program for skincare professionals further strengthen its competitive position. Additionally, Dermata's strategic shift to DTC and B2B channels aims to reduce regulatory burdens and accelerate commercialization, leveraging clinical knowledge and consumer trends toward natural, science-backed skincare solutions.

Risks overview
Risks summary
The primary risks for Dermata include successful commercialization of new products, regulatory compliance, financial sustainability, and competitive pressures in the skincare market.
Risks details:

• Commercialization Risk: Dermata's success depends on effective market acceptance and sales of its new Tome skincare products in a competitive environment.
• Regulatory Risk: Although shifting to OTC and cosmetic products reduces regulatory burden, compliance with applicable regulations remains critical.
• Financial Risk: The company reported net losses and has limited cash reserves, which may require additional financing to support operations and growth.
• Competitive Risk: The skincare market is crowded with established brands and emerging products, posing challenges to Dermata's market share acquisition.
• Product Development Risk: Delays or failures in clinical trials or product development could hinder Dermata's ability to launch and expand its product portfolio.

FINAL FORECAST FOR DRMA

Final take one line
Dermata Therapeutics is transitioning from prescription acne treatments to direct-to-consumer and OTC skincare products leveraging proprietary Bioneedle technology with strong clinical and market positioning.
Final take 12 to 24 month view

Business trends: Increasing consumer preference for natural, science-backed, multifunctional skincare products and OTC treatments for common skin conditions.
Execution milestones: Launch of Tome Foundational and Clearing Treatments in mid-2026, enrollment in clinical trials, expansion of product portfolio and professional certification network.
Key risks: Commercialization challenges, regulatory compliance, financial sustainability, competitive market pressures, and product development uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Dermata Therapeutics, Inc. is a scientific leader in skincare focused on developing and commercializing products addressing common and underserved skin conditions [S1].
  • Originally focused on prescription (Rx) products, Dermata's lead asset was XYNGARI (DMT310), studied in clinical trials for moderate-to-severe acne, with statistically significant Phase 3 STAR-1 trial results announced in March 2025 [S1].
  • In September 2025, Dermata strategically shifted from Rx acne development to direct-to-consumer (DTC) and business-to-business (B2B) skincare products, aiming for faster commercialization and reduced regulatory burden [S1].
  • The company leverages its proprietary ingredient, Spongilla lacustris, a freshwater sponge processed into a purified powder called Bioneedle, used in cosmetic and OTC skincare treatments [S1].
  • Dermata plans to launch its first cosmetic product, Tome Foundational Treatment, in mid-2026, followed shortly by the Tome Clearing Treatment, an OTC acne product [S1].
  • The company intends to sell products via its website with monthly subscriptions and to medical professionals for in-office treatments [S1].
  • Dermata aims to expand its OTC product portfolio using Bioneedle technology to treat various skin diseases including psoriasis and seborrheic dermatitis [S1].
  • The company plans to build a network of certified skincare professionals through a certification program to market its products [S1].
  • Dermata is exploring partnerships and licensing to complement its product portfolio and expand commercialization globally [S1].
  • The skincare market is large and growing, with consumer trends favoring natural, science-backed, multifunctional cosmetic and OTC products [S1].
  • Acne affects over 50 million people in the US, with many consumers initially using OTC products before seeking prescription treatments [S1].
  • Dermata's Bioneedle technology may enable non-invasive intradermal delivery of botulinum toxins for aesthetic and medical skin conditions [S1].
  • Recent financial snapshot as of September 30, 2026: cash and equivalents $4.82 million, current assets $6.43 million, current liabilities $1.52 million, current ratio 4.24, cash ratio 3.18, net loss $2.82 million, basic and diluted EPS -$0.55 [S2].
  • Dermata announced enrollment of the first participant in the Tome Clearing Treatment clinical trial in November 2026 [N1].
  • The company reported Q2 2026 results ahead of its first product launch in August 2026 [N3].
  • Dermata announced a private placement valued up to $12.4 million in December 2025 [N4].
  • The first OTC acne kit launch was announced for mid-2026 [N5].
  • Dermata completed enrollment in the DMT310 Phase 3 STAR-1 trial in December 2024 [N7].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-03 | www.nasdaq.com | Dermata Therapeutics, Inc. Announces Enrollment of First Participant in Tome Clearing Treatment Clinical Trial | https://www.nasdaq.com/articles/dermata-therapeutics-inc-announces-enrollment-first-participant-tome-clearing-treatment
  • N2 | 2026-09-09 | www.nasdaq.com | Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus | https://www.nasdaq.com/articles/biotech-movers-modular-medical-jumps-innovage-revenue-16-pyxis-data-deck-dogwood-focus
  • N3 | 2026-08-12 | www.nasdaq.com | Dermata Therapeutics Reports Q2 2026 Results Ahead Of First Product Launch; Stock Up | https://www.nasdaq.com/articles/dermata-therapeutics-reports-q2-2026-results-ahead-first-product-launch-stock
  • N4 | 2025-12-26 | www.nasdaq.com | Dermata Therapeutics Announces A Private Placement Valued At Up To $12.4 Mln | https://www.nasdaq.com/articles/dermata-therapeutics-announces-private-placement-valued-124-mln
  • N5 | 2025-12-08 | www.nasdaq.com | Dermata Therapeutics To Launch First OTC Acne Kit In Mid-2026 | https://www.nasdaq.com/articles/dermata-therapeutics-launch-first-otc-acne-kit-mid-2026
  • N6 | 2025-08-13 | www.nasdaq.com | Dermata Posts Narrower Loss in Q2 | https://www.nasdaq.com/articles/dermata-posts-narrower-loss-q2
  • N7 | 2024-12-03 | www.nasdaq.com | Dermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial | https://www.nasdaq.com/articles/dermata-therapeutics-completes-enrollment-dmt310-phase-3-star-1-trial
  • N8 | 2024-08-06 | www.nasdaq.com | 3 Penny Stocks to Watch Now, 8/6/24 | https://www.nasdaq.com/articles/3-penny-stocks-watch-now-8-6-24
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine